STOCK TITAN

Journey Medical (DERM) CFO receives new RSU and stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Journey Medical Corp CFO Joseph Benesch received new equity awards as part of his compensation. On April 22, 2026, he was granted 28,907 restricted stock units that vest in three annual installments from April 2027 through April 2029. He also received 41,860 stock options with an exercise price of $5.04 per share, vesting annually over the same three-year period and expiring in 2036. After these awards, he directly holds 261,371 shares of common stock, and has 41,860 options outstanding.

Positive

  • None.

Negative

  • None.
Insider Benesch Joseph
Role CFO
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 41,860 $0.00 --
Grant/Award Common Stock, $0.0001 par value 28,907 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 41,860 shares (Direct, null); Common Stock, $0.0001 par value — 261,371 shares (Direct, null)
Footnotes (1)
  1. On April 22, 2026, the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 9,636 shares on April 22, 2027, 9,636 shares on April 22, 2028 and 9,635 shares on April 22, 2029. Includes restricted stock units, which vest over various time periods. On April 22, 2026, the reporting person was granted 41,860 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 13,953 shares on April 22, 2027, 13,953 shares on April 22, 2028 and 13,954 shares on April 22, 2029.
RSU grant 28,907 units Restricted stock units granted on April 22, 2026
Option grant size 41,860 options Stock options granted on April 22, 2026
Option exercise price $5.04 per share Strike price for stock options
Options expiration April 22, 2036 Expiration date of stock options
Shares held after grant 261,371 shares Common stock directly owned after transactions
Options held after grant 41,860 options Total options directly owned after transactions
First RSU vesting 9,636 units Vest on April 22, 2027
Final RSU vesting 9,635 units Vest on April 22, 2029
restricted stock units financial
"the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 5.0400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
2015 Stock Plan financial
"pursuant to the Issuer's 2015 Stock Plan, as amended"
expiration date financial
"expiration_date: 2036-04-22T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Benesch Joseph

(Last)(First)(Middle)
C/O JOURNEY MEDICAL CORPORATION
9237 E VIA DE VENTURA BLVD., SUITE 105

(Street)
SCOTTSDALE ARIZONA 85258

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Journey Medical Corp [ DERM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, $0.0001 par value04/22/2026A28,907(1)A$0261,371(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$5.0404/22/2026A41,860 (3)04/22/2036Common Stock, $0.0001 par value41,860$041,860D
Explanation of Responses:
1. On April 22, 2026, the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 9,636 shares on April 22, 2027, 9,636 shares on April 22, 2028 and 9,635 shares on April 22, 2029.
2. Includes restricted stock units, which vest over various time periods.
3. On April 22, 2026, the reporting person was granted 41,860 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 13,953 shares on April 22, 2027, 13,953 shares on April 22, 2028 and 13,954 shares on April 22, 2029.
/s/ Ramsey Alloush, attorney-in-fact04/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Journey Medical (DERM) CFO Joseph Benesch receive in this Form 4?

CFO Joseph Benesch received 28,907 restricted stock units and 41,860 stock options. These equity awards are compensation grants that give him future rights to Journey Medical common shares if vesting conditions are satisfied over several years.

How do the new restricted stock units for Journey Medical (DERM) CFO vest?

The 28,907 restricted stock units vest in three annual tranches: 9,636 units on April 22, 2027, another 9,636 on April 22, 2028, and 9,635 on April 22, 2029. Each vesting date delivers actual Journey Medical shares if conditions are met.

What are the terms of the stock options granted to Journey Medical (DERM) CFO?

The CFO received 41,860 stock options with a $5.04 exercise price. These options vest in three equal annual installments from April 22, 2027 through April 22, 2029, and expire on April 22, 2036 if they are not exercised into common shares.

How many Journey Medical (DERM) shares does the CFO hold after these awards?

Following these grants, CFO Joseph Benesch directly holds 261,371 shares of Journey Medical common stock. This figure includes restricted stock units that vest over various time periods, as disclosed in the filing’s footnotes describing his equity position.

Is the Journey Medical (DERM) Form 4 a stock purchase or a compensation grant?

This Form 4 reflects compensation grants, not market purchases or sales. The transactions are coded “A” for awards, granting restricted stock units and stock options at no cash cost to the CFO, subject to multi-year vesting schedules under the company’s stock plan.